LJ100 New Published Human Clinical Research 2014

Another double blind placebo controlled human clinical on LJ100 was just published in Jan 2014,
and a review paper on LJ100 as natural alternative to testosterone replacement
therapy was published on First International Journal on Andrology (2014).

This brings our published human clinicals to 12 total. We have 3 additional clinicals that are on going as well.


Effects of LJ100 on Sexual Performance & Well-being in Men with Reduced Sexual

2Udani J,  1Gruenwald
J, 1 Miller M, 1George A, 1Mufiza M, Abas A,

Published:  Evidence-Based Complementary and Alternative Medicine, Volume 2014, Article ID: 179529



This study was conducted to determine the efficacy and safety of LJ100 in improving
sexual performance and quality of life. Safety and tolerability was monitored
by blood biochemistry and adverse event observation.



A total of 26 men with mild erectile dysfunction were recruited in a placebo
controlled double blind study and randomly assigned to one of two groups;
200mg/day of LJ100 or placebo. After a screening visit, subjects returned for a
baseline visit and began collecting data on their sexual performance using a
set of validated questionnaires including: Percentage of Successful Sexual
Intercourse Attempts (SIA), Erection Hardness Scale (EHS), Sexual Health
Inventory (SHIM), and Aging Male Symptom Score (AMS). Subjects received 12
weeks of treatment and independent t- test was performed to determine if the
active and placebo group were significantly different. The results for this
abstract are based on an interim analysis.



The subjects in the LJ100 treatment group demonstrated statistically significant
(p<0.05) higher scores than the placebo group at 12 weeks in the following endpoints:
Erection Hardness Scale score, Aging Males Symptom Score, and the Sexual Health
Inventory for Men. The Sexual Intercourse Assessment (SIA) measured several
parameters which were specific to each intercourse attempt. The LJ100 group was
statistically significantly higher than the Placebo group at 12 weeks on the
following scores: “Overall were you satisfied with this sexual experience?”,
“Overall were you satisfied with the hardness of your erection?”, “Were you
able to insert your entire penile shaft into your partner’s vagina?”, “Were you
able to achieve at least some erection?”, and “Did your erection last long
enough for you to have successful intercourse?”.  There is also a reducing
trend of Fat Mass Loss (Dexa scan) in the LJ100 group in overweight subjects
(>25kg BMI) of fat mass loss in waist and hips compared to placebo. Total
Testosterone for LJ100 group increase from 359.23 to 396.46 (10.36% increase)


Phytoandrogenic properties of Eurycoma longifolia as natural alternative to testosterone replacement therapy

A. George1 & R.

Published: First International Journal on Andrology (2014)

The testosterone deficiency syndrome (TDS) is characterised by numerous symptoms,
including low libido, increased fat mass, fatigue, erectile dysfunction or
osteoporosis, and up to 80% of men will experience some kind of ageing males’
symptoms. This is caused by the age-depending decline in serum testosterone
levels with concentrations being about 40–50% lower in men older than 60 years
compared with young men. This significant decline in testosterone levels is
further closely linked with medical conditions such as obesity, metabolic
syndrome, diabetes or hypertension. The conventional way of treating TDS is the
testosterone replacement therapy (TRT), for which preparations are on the
market. Apart from the beneficial effects of TRT, significant adverse side
effects have been described, and prostate cancer (PCa) as absolute
contraindication is debated. Eurycoma longifolia (Tongkat Ali; TA) is natural
alternative to TRT and has been shown to restore serum testosterone levels,
thus significantly improving sexual health. This includes significant positive
effects on bone health and physical condition of patients. In addition, a
significant antihyperglycaemic effect and cytotoxicity against PCas cells has
been shown. Thus far, at therapeutic concentrations, no significant side
effects of the treatment were obvious. Therefore, TA might be a safe
alternative to TRT.



HP Ingredients